UA41265C2 - Кристалічна форма (-)-цис-4-аміно-1-(2-гідроксиметил-1,3-оксатіолан-5-іл)-(1н)-піримідин-2-ону (варіанти), способи її отримання та фармацевтична композиція - Google Patents

Кристалічна форма (-)-цис-4-аміно-1-(2-гідроксиметил-1,3-оксатіолан-5-іл)-(1н)-піримідин-2-ону (варіанти), способи її отримання та фармацевтична композиція

Info

Publication number
UA41265C2
UA41265C2 UA93004068A UA93004068A UA41265C2 UA 41265 C2 UA41265 C2 UA 41265C2 UA 93004068 A UA93004068 A UA 93004068A UA 93004068 A UA93004068 A UA 93004068A UA 41265 C2 UA41265 C2 UA 41265C2
Authority
UA
Ukraine
Prior art keywords
pyrimidin
cis
amino
spoyatos
oxatiolan
Prior art date
Application number
UA93004068A
Other languages
English (en)
Russian (ru)
Inventor
Пол РАВЕНСКРОФТ
Тоні Гордон РОБЕРТС
Пол ЕВАНС
Original Assignee
Глексо Груп Лімітед
Глексо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10696001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA41265(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глексо Груп Лімітед, Глексо Груп Лимитед filed Critical Глексо Груп Лімітед
Publication of UA41265C2 publication Critical patent/UA41265C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Secondary Cells (AREA)
  • Medicinal Preparation (AREA)
UA93004068A 1991-06-03 1992-02-06 Кристалічна форма (-)-цис-4-аміно-1-(2-гідроксиметил-1,3-оксатіолан-5-іл)-(1н)-піримідин-2-ону (варіанти), способи її отримання та фармацевтична композиція UA41265C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919111902A GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds
PCT/EP1992/001213 WO1992021676A1 (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives

Publications (1)

Publication Number Publication Date
UA41265C2 true UA41265C2 (uk) 2001-09-17

Family

ID=10696001

Family Applications (1)

Application Number Title Priority Date Filing Date
UA93004068A UA41265C2 (uk) 1991-06-03 1992-02-06 Кристалічна форма (-)-цис-4-аміно-1-(2-гідроксиметил-1,3-оксатіолан-5-іл)-(1н)-піримідин-2-ону (варіанти), способи її отримання та фармацевтична композиція

Country Status (30)

Country Link
US (1) US5905082A (uk)
EP (2) EP0517145B1 (uk)
JP (1) JP2851480B2 (uk)
KR (1) KR100244008B1 (uk)
AP (1) AP300A (uk)
AT (1) ATE212630T1 (uk)
AU (2) AU656379B2 (uk)
BG (1) BG60914B1 (uk)
CA (2) CA2070230C (uk)
CZ (1) CZ284513B6 (uk)
DE (1) DE69232387T2 (uk)
DK (1) DK0517145T3 (uk)
ES (1) ES2171158T3 (uk)
GB (1) GB9111902D0 (uk)
GE (1) GEP19991834B (uk)
IE (2) IE921780A1 (uk)
IL (1) IL102073A (uk)
IS (2) IS1867B (uk)
MX (1) MX9202619A (uk)
NO (1) NO301713B1 (uk)
NZ (1) NZ242981A (uk)
OA (1) OA09913A (uk)
PT (1) PT517145E (uk)
RU (1) RU2102393C1 (uk)
SG (1) SG52455A1 (uk)
SK (1) SK281249B6 (uk)
TW (1) TW254939B (uk)
UA (1) UA41265C2 (uk)
WO (1) WO1992021676A1 (uk)
ZA (1) ZA924007B (uk)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581979A (en) * 1983-07-01 1986-04-15 Automotive Products Plc Shipping and installation restraining clip for master cylinder input member
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
DK0831852T3 (da) 1995-06-07 2007-03-19 Univ Emory Nukleosider med anti-hepatitis B-virusaktivitet
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
JP2000515852A (ja) 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CN1503796B (zh) * 2001-03-01 2012-07-04 三角药品公司 顺-ftc的多晶型物及其它晶型
US6600044B2 (en) 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
WO2003027106A1 (en) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Process for the preparation of crystalline polymorph ii of lamivudine
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
JP2006508134A (ja) * 2002-11-08 2006-03-09 グラクソ　グループ　リミテッド 医薬組成物
SI1583542T1 (sl) * 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
CN101056890B (zh) * 2004-11-10 2012-05-09 诺华疫苗和诊断公司 脱酰胺基干扰素-β
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CA2649796A1 (en) * 2006-04-18 2007-10-25 Lupin Limited A novel crystalline form of lamivudine
WO2009031026A2 (en) * 2007-09-06 2009-03-12 Combino Pharm, S.L. Novel pharmaceutical compositions
US20100190982A1 (en) * 2007-09-17 2010-07-29 Janardhana Rao Vascuri Process for the preparation of lamivudine form i
BRPI0820224A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Composto de fórmula iii ou seus estereoisômeros; processo para sua preparação e seu uso; uso de um composto de formula iii(a) ou iii(b) em um processo para a preparação de lamivudina de fórmula i(a) ou um composto de fórmula i(c); processo para preparação de lamivudina de fórmula i(a)
WO2009069013A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Crystalline form i of lamivudine and its preparation
SI2225232T1 (sl) * 2007-11-29 2012-12-31 Ranbaxy Laboratories Limited Postopek za pripravo substituiranih 1,3-oksatiolanov
WO2009127996A1 (en) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Novel crystalline form of lamivudine
WO2010023676A2 (en) * 2008-09-01 2010-03-04 Hetero Research Foundation Process for preparing lamivudine polymorph form
US20110288298A1 (en) * 2008-11-12 2011-11-24 Lupin Limited novel polymorph of emtricitabine and a process for preparing of the same
CN101531656B (zh) * 2009-03-24 2010-12-08 福建广生堂药业有限公司 拉米夫定晶型及其制备方法
CN101993439B (zh) * 2009-03-24 2013-04-24 福建广生堂药业股份有限公司 拉米夫定晶型及其制备方法
EP2435052B1 (en) * 2009-05-27 2015-07-15 Hetero Research Foundation Solid oral dosage forms of lamivudine with isomalt
US8710218B2 (en) 2009-07-15 2014-04-29 Lupin Limited Process for preparation of Efavirenz
WO2011045815A2 (en) 2009-10-14 2011-04-21 Matrix Laboratories Ltd. Process for the preparation of lamivudine and novel salts in the manufacture thereof
RS54123B1 (sr) 2010-01-27 2015-12-31 Viiv Healthcare Company Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
US20120295930A1 (en) * 2010-02-03 2012-11-22 Shankar Rama Novel process for the preparation of cis-nucleoside derivative
WO2011100381A1 (en) * 2010-02-12 2011-08-18 Merck Sharp & Dohme Corp. Preparation of lamivudine form i
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
EP2739620A1 (en) 2011-08-05 2014-06-11 Lupin Limited A stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CN114099454B (zh) * 2020-08-31 2023-06-27 长春海悦药业股份有限公司 一种拉米夫定片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
JPH04358486A (ja) * 1991-06-04 1992-12-11 Toshiba Corp 高能率符号化信号処理装置

Also Published As

Publication number Publication date
MX9202619A (es) 1992-12-01
JPH06211848A (ja) 1994-08-02
KR930000511A (ko) 1993-01-15
HK1009599A1 (en) 1999-06-04
CZ261293A3 (en) 1994-04-13
CA2311988A1 (en) 1992-12-04
ES2171158T3 (es) 2002-09-01
TW254939B (uk) 1995-08-21
US5905082A (en) 1999-05-18
IE921780A1 (en) 1992-12-16
AU1881092A (en) 1993-01-08
NO922182L (no) 1992-12-04
RU2102393C1 (ru) 1998-01-20
NO922182D0 (no) 1992-06-02
IS3873A (is) 1992-12-04
SK125793A3 (en) 1994-11-09
IE20020782A1 (en) 2003-04-02
EP0517145A1 (en) 1992-12-09
IS4268A (is) 1995-02-27
IL102073A0 (en) 1993-01-14
ZA924007B (en) 1993-04-28
CA2070230C (en) 2004-08-03
PT517145E (pt) 2002-07-31
OA09913A (en) 1994-09-15
EP1099700A1 (en) 2001-05-16
SK281249B6 (sk) 2001-01-18
DE69232387D1 (de) 2002-03-14
BG60914B1 (bg) 1996-06-28
KR100244008B1 (ko) 2000-03-02
IL102073A (en) 1996-05-14
NO301713B1 (no) 1997-12-01
SG52455A1 (en) 1998-09-28
GB9111902D0 (en) 1991-07-24
AP9200395A0 (en) 1992-07-31
ATE212630T1 (de) 2002-02-15
AU656379B2 (en) 1995-02-02
BG98254A (bg) 1994-07-29
DE69232387T2 (de) 2002-09-26
AP300A (en) 1994-01-20
DK0517145T3 (da) 2002-05-06
GEP19991834B (en) 1999-11-05
CA2311988C (en) 2005-11-15
JP2851480B2 (ja) 1999-01-27
CZ284513B6 (cs) 1998-12-16
CA2070230A1 (en) 1992-12-04
AU1736192A (en) 1993-03-11
NZ242981A (en) 1994-04-27
EP0517145B1 (en) 2002-01-30
WO1992021676A1 (en) 1992-12-10
IS1867B (is) 2003-05-02

Similar Documents

Publication Publication Date Title
UA41265C2 (uk) Кристалічна форма (-)-цис-4-аміно-1-(2-гідроксиметил-1,3-оксатіолан-5-іл)-(1н)-піримідин-2-ону (варіанти), способи її отримання та фармацевтична композиція
RU93058495A (ru) Кристаллические производные оксатиолана, способ их получения, фармацевтическая композиция на их основе
CZ283765B6 (cs) 1,3-Oxathiolannukleosidové analogy
RU94013464A (ru) Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции
BG60698B2 (en) Pharmaceutical ACCEPTABLE SALTS
PT97638A (pt) Processo para a preparacao de compostos peptidicos e de composicoes farmaceuticas que os contem
EE03148B1 (et) Kristallilise magneesiumomeprasooli ravimvorm, selle valmistamise protsess ja kasutamine
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
SE8700499L (sv) Nya farmakologiskt aktiva foreningar
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
RU93045710A (ru) Противовирусная нуклеозидная композиция, способ ее получения и способ лечения
GB0206860D0 (en) Compounds
NL300027I1 (nl) Omeprazole-derivaten.
HUP9801571A2 (hu) Zidovudin, 1592U89 és 3TC vagy FTC szinergetikus kombinációi
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
CY1109711T1 (el) Νεα κρυσταλλικη μορφη υδροχλωριουχου λερκανιδιπινης και διαδικασιες για την παρασκευη τους
ES2009723A4 (es) Derivados de acidos biliares, procedimientos para la preparacion de los mismos y composiciones farmaceuticas conteniendolos.
FI934298A0 (fi) Kristallin tiagabine-hydrokloridmonohydrat, dess framstaellning och dess anvaendning
ATE82681T1 (de) 2',3'-dideoxy-3'-fluorothymidin und verwandte verbindungen zur behandlung von adenovirusinfektionen.
IT8423263A1 (it) Formulazioni farmaceutiche acquose di piroxicam monoidrato
FI843560A7 (fi) Mevalonolaktonin analogeja ja niiden johdannaisia, menetelmiä niiden valmistamiseksi, niitä sisältäviä farmaseuttisia yhdistelmiä ja niide n käyttö farmaseuttisina aineina.
DE69102704D1 (de) Orales, melatonin enthaltendes arzneimittel.
DK0556322T3 (da) Aminosulfonylurinstof-ACAT-inhibitorer
UA48958C2 (uk) 9-o-оксимові похідні еритроміцину а та фармацевтична композиція на їх основі